XML 91 R65.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Surface Acquisition (Details) $ / shares in Units, $ in Thousands |  | 4 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 08, 2023 USD ($) item $ / shares shares | Dec. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($)
Surface Acquisition |  |  |  |
Goodwill |  | $ 943 | $ 943 | $ 943
Surface Oncology, Inc. |  |  |  |
Surface Acquisition |  |  |  |
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares | 0.1960 |  |  |
Share price | $ / shares | $ 5.2831 |  |  |
Contingent value right per share | item | 1 |  |  |
Contingent value rights payment period | 10 years |  |  |
Business combination consideration transferred | $ 64,596 |  |  |
Business Combination, Number of Shares Issued to Former Employees of Acquiree shares | shares | 161,100 |  |  |
Goodwill | $ 0 |  |  |
Business Combination, Number of Out Licensed Partnership Program | item | 2 |  |  |
Revenue of Acquiree since Acquisition Date |  | 0 |  |
Earnings or Loss of Acquiree since Acquisition Date |  | $ (5,900) |  |
Acquisition related costs |  |  | $ 5,100 |
Surface Oncology, Inc. | Surface GSK Agreement |  |  |  |
Surface Acquisition |  |  |  |
Milestone and royalty based CVR payments (as percent) | 70.00% |  |  |
Surface Oncology, Inc. | Surface Novartis Agreement |  |  |  |
Surface Acquisition |  |  |  |
Milestone and royalty based CVR payments (as percent) | 70.00% |  |  |
Surface Oncology, Inc. | Surface's SRF114 proprietary drug product candidate |  |  |  |
Surface Acquisition |  |  |  |
Upfront payment based CVR payments (as percent) | 25.00% |  |  |
Surface Oncology, Inc. | Surface's SRF388 proprietary drug product candidate |  |  |  |
Surface Acquisition |  |  |  |
Upfront payment based CVR payments (as percent) | 50.00% |  |  |

X
- Definition The payment period of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of milestone and royalty based payments payable as part of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of upfront payments payable as part of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of contingent value rights issuable in consideration for each share under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPerShare
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of outlicensed partnership program in a business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued in exchange of each share of acquiree in a business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree
Namespace Prefix: | chrs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued to former employees of acquiree. + References No definition available. + Details
Name: | chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares
Namespace Prefix: | chrs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceNovartisAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |